Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Theravance is the last of the three sponsors from a marathon advisory committee review of antibiotics for cSSSI to get an action letter; as the only one with a positive vote, it’s the only one that doesn’t need further trials.
You may also be interested in...
Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance
Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area
Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance
Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area
Approval Delays for J&J/Basilea's Ceftobiprole Shake Partnership
Basilea has become so frustrated with partner Johnson & Johnson's efforts--or lack thereof--to get anti-infective ceftobiprole past the regulators that it has resorted to arbitration. The biotech had few other options, but probably has most to lose.